SODIUM PYROPHOSPHATE

Possibly Marketed Outside US

First approved in 1955

Details

Stereochemistry	ACHIRAL
Molecular Formula	4Na.O7P2
Molecular Weight	265.9024
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O

InChI

InChIKey=FQENQNTWSFEDLI-UHFFFAOYSA-J

InChI=1S/4Na.H4O7P2/c;;;;1-8(2,3)7-9(4,5)6/h;;;;(H2,1,2,3)(H2,4,5,6)/q4*+1;/p-4

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	O7P2
Molecular Weight	173.9433
Charge	-4
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://books.google.ru/books?id=cPjjBwAAQBAJ&printsec=frontcover&hl=ru#v=onepage&q&f=false
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11401820 | https://www.ncbi.nlm.nih.gov/pubmed/27061894 | http://www.food-info.net/uk/e/e450.htm

Inorganic pyrophosphate (PPi ) has long been known as a by-product of many intracellular biosynthetic reactions. PPi plays the regulatory role in living systems, such as activities of enzymes, fidelity of syntheses of macromolecules, and proliferation of cells. PPi is used as a biochemical energy source instead of ATP especially in bacteria, protists, and plants. PPi may also regulate the formation and dissolution of bone as well as pathologic calcification of soft tissues and the formation of urinary stones. The formation of calcium pyrophosphate dihydrate crystals in the extracellular fluids of joints cause the disease called pseudogout. Sodium, potassium and calcium pyrophosphates (E450) are used as food additives as buffers and emulsifiers.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
bone mineralization 5 Target ID: GO:0030282 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27061894	Modulator 846

Conditions

Condition	Modality	Highest Phase	Product
Gastrointestinal bleeding 13 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30046b6b-09ea-46b1-8e60-61c53e1e7282	Diagnostic	Approved 8583	Stannous Pyrophosphate Approved Use https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30046b6b-09ea-46b1-8e60-61c53e1e7282
Bone Diseases 5 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30046b6b-09ea-46b1-8e60-61c53e1e7282 https://www.ncbi.nlm.nih.gov/pubmed/22459337	Diagnostic	Approved 8583	Stannous Pyrophosphate Approved Use https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30046b6b-09ea-46b1-8e60-61c53e1e7282
Acute myocardial infarction 37 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30046b6b-09ea-46b1-8e60-61c53e1e7282 https://www.ncbi.nlm.nih.gov/pubmed/22459337 https://www.ncbi.nlm.nih.gov/pubmed/3033570	Diagnostic	Approved 8583	Stannous Pyrophosphate Approved Use https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30046b6b-09ea-46b1-8e60-61c53e1e7282

PubMed

Title	Date	PubMed
Hepatitis C virus helicase/NTPase: an efficient expression system and new inhibitors.	2008-06	18620531
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.	2008-04-10	18327899
Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.	2005-01	15616314
Biochemical characterization of HIV-1 reverse transcriptases encoding mutations at amino acid residues 161 and 208 involved in resistance to phosphonoformate.	1998-12-15	9973178
Identification of the amino acid in the human immunodeficiency virus type 1 reverse transcriptase involved in the pyrophosphate binding of antiviral nucleoside triphosphate analogs and phosphonoformate. Implications for multiple drug resistance.	1993-12-14	7506027
Nucleoside triphosphates promote the transformation of Ah receptor to its DNA-binding form.	1991-03-01	1848756
PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptase.	1986-05	2425731
Antiviral effects of phosphonoformate (PFA, foscarnet sodium).	1982	6201932
Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase.	1980-03-28	6245699

Patents

Sample Use Guides

In Vivo Use Guide

Acceptable Daily Intake: Up to 70 mg/kg bodyweight for all pyrophosphate containing food additives

Route of Administration: Oral

In Vitro Use Guide

pyrophosphoric acid at the concentration of 0.1 - 1.0 mM does not affect spore germination of Streptomyces galilaeus ATCC 31133.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:06:50 GMT 2025` Edited by `admin` on `Mon Mar 31 18:06:50 GMT 2025`
Record UNII	O352864B8Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SODIUM PYROPHOSPHATE

Official Name

English

Tetrasodium pyrophosphate

Preferred Name

English

SODIUM PYROPHOSPHATE [USAN]

Common Name

English

TETRASODIUM DIPHOSPHATE

Systematic Name

English

TETRASODIUM PYROPHOSPHATE [MI]

Common Name

English

SODIUM PYROPHOSPHATE [HSDB]

Common Name

English

SODIUM PYROPHOSPHATE [FCC]

Common Name

English

SODIUM PYROPHOSPHATE [II]

Common Name

English

NSC-56751

Code

English

Sodium pyrophosphate [WHO-DD]

Common Name

English

SODIUM PYROPHOSPHATE [VANDF]

Common Name

English

DIPHOSPHORIC ACID, TETRASODIUM SALT

Common Name

English

SODIUM PYROPHOSPHATE [MART.]

Common Name

English

Classification Tree Code System Code

DSLD

2418 (Number of products:6)